Kim et al. (2018) combined SGT-53 with anti-programmed cell death protein 1 (PD1) antibody and demonstrated that SGT-53 sensitized otherwise refractory tumors to anti-PD1 antibody in three mouse tumor models, including glioblastoma. In later data, SGT-53 was shown to enhance antitumor immunity and sensitize glioblastoma to anti-PD-1 therapies by converting immunologically “cold” tumors into “hot” tumors (Kim et al., 2018). This evidence concerns the gene PDCD1 and neoplasm.